Open AccessAdjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
Author(s) -
Zhongyuan Yin,
Zhiming Zhao,
Wenbo Tang,
Nan Jiang,
Kedi Zhang,
Yu-Yao Song,
Yan Wang,
Chenggang Li,
Yu Gao,
Rong Liu
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i13.2778
Subject(s) - medicine , gemcitabine , pancreatic ductal adenocarcinoma , adverse effect , adjuvant , paclitaxel , gastroenterology , oncology , chemotherapy , pancreatic cancer , cancer
Nab-paclitaxel plus gemcitabine (AG) has resulted in higher tumor response and survival rates for metastatic or advanced pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone.